Literature DB >> 19582459

Annual costs of rheumatoid arthritis in Turkey.

Simten Malhan1, Lale Aktekin Akbulut, Hatice Bodur, Cankat F Tulunay.   

Abstract

Objective of the present study is aimed to determine costs of rheumatoid arthritis (RA) based on reimbursement agencies perspective [Social Security Institution (SSI)] in Turkey. The international clinical guidelines for RA are followed for analysing the direct costs. Data were collected from hospital bills, social security institution price lists, and Ministry of Health drug price list. Direct costs of RA patients were estimated as euro 2,669.14 patient/year. Outpatient costs were found to be euro 240.40. Routine tests during the year were calculated as euro 98.85. Ten percent of patients are hospitalized per year, and 0.62% of these patients received arthroplasty and/or other interventions. The cost during hospital stay was euro 87.76. euro 2,238 was determined as being paid per year for medication alone (including anti-TNF) and euro 4 is spent on auxiliary materials annually. Our data show a remarkable economic impact of RA over society. We hope that the cost of RA studies will help package price practices for reimbursement agencies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582459     DOI: 10.1007/s00296-009-1040-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  17 in total

1.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

Review 2.  OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis.

Authors:  Sherine Gabriel; Michael Drummond; Andreas Maetzel; Maarten Boers; Doug Coyle; Vivian Welch; Peter Tugwell
Journal:  J Rheumatol       Date:  2003-04       Impact factor: 4.666

Review 3.  Cost of illness studies in rheumatic diseases.

Authors:  Bruno Fautrel; Francis Guillemin
Journal:  Curr Opin Rheumatol       Date:  2002-03       Impact factor: 5.006

4.  Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.

Authors:  Andreas Maetzel; Peter Tugwell; Maarten Boers; Francis Guillemin; Doug Coyle; Mike Drummond; John B Wong; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2003-04       Impact factor: 4.666

5.  Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study.

Authors:  A E Clarke; H Zowall; C Levinton; H Assimakopoulos; J T Sibley; M Haga; J Shiroky; C Neville; D P Lubeck; S A Grover; J M Esdaile
Journal:  J Rheumatol       Date:  1997-06       Impact factor: 4.666

Review 6.  Economic burden of rheumatoid arthritis: a systematic review.

Authors:  N J Cooper
Journal:  Rheumatology (Oxford)       Date:  2000-01       Impact factor: 7.580

7.  Prevalence of rheumatoid arthritis in Antalya, Turkey.

Authors:  C Kaçar; E Gilgil; T Tuncer; B Bütün; S Urhan; V Arikan; U Dündar; M C Oksüz; G Sünbüloğlu; C Yildirim; I Tekeoğlu; G Yücel
Journal:  Clin Rheumatol       Date:  2004-11-13       Impact factor: 2.980

8.  Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  H Bodur; S Ataman; L Akbulut; D Evcik; V Kavuncu; T Kaya; R Günaydin; B Kuran; N Kotevoğlu; A Bal; E Aydoğ; Z Altay; H Uğurlu; H Kocabaş; N Olmez; P Yazgan; S Gürsoy; E Madenci; S Ozel; S U Delialioğlu
Journal:  Clin Rheumatol       Date:  2008-03-21       Impact factor: 2.980

9.  TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.

Authors:  G Kobelt; K Eberhardt; P Geborek
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

Review 10.  Epidemiology and genetics of rheumatoid arthritis.

Authors:  Alan J Silman; Jacqueline E Pearson
Journal:  Arthritis Res       Date:  2002-05-09
View more
  2 in total

1.  Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims Database.

Authors:  Onur Baser; Abdulkadir Burkan; Erdem Baser; Rasim Koselerli; Emre Ertugay; Akif Altinbas
Journal:  Rheumatol Int       Date:  2013-05-25       Impact factor: 2.631

2.  Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey.

Authors:  Onur Baser; Erdem Baser; Akif Altinbas; Abdulkadir Burkan
Journal:  Health Econ Rev       Date:  2013-03-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.